

Appln No.: 10/828,394
Amendment Dated: November 30, 2005
Reply to Office Action of October 3, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method for treatment of a cancerous angiogenesis-related disease, comprising ~~the steps of~~ administering to an individual suffering from a cancerous angiogenesis-related disease an amount of a therapeutic oligonucleotide composition effective to reduce the effective amount of clusterin in the individual.
2. (currently amended) The method of claim 1, wherein the therapeutic oligonucleotide composition comprises an antisense oligonucleotide complementary to the sequence of human clusterin (Seq. ID. No. 1).
3. (original) The method of claim 2, wherein the antisense oligonucleotide is selected from the group consisting of oligonucleotides whose sequence consists essentially of a sequence as set forth in Seq. ID Nos. 2- 15.
4. (withdrawn, currently amended) The method of claim 1, wherein the therapeutic oligonucleotide composition comprises an RNAi agent.
5. (withdrawn) The method of claim 4, wherein the RNAi agent is selected from the group consisting of oligonucleotides whose sequence consists essentially of a sequence as set forth in Seq. ID Nos. 16 to 23 or a sequence complementary thereto.
6. (currently amended) A method for reducing angiogenesis in a cancerous angiogenesis-related disease, comprising ~~the steps of~~ treating cells of the cancer with amount of a therapeutic oligonucleotide composition effective to reduce the effective amount of clusterin in the cells, and thereby to reduce the occurrence of angiogenesis.
7. (currently amended) The method of claim 6, wherein the therapeutic oligonucleotide composition comprises an antisense oligonucleotide complementary to the sequence of human clusterin (Seq. ID. No. 1).
8. (original) The method of claim 7, wherein the antisense oligonucleotide is selected from the group consisting of oligonucleotides whose sequence consists essentially of a sequence as set forth in Seq. ID Nos. 2- 15.

Appln No.: 10/828,394

Amendment Dated: November 30, 2005

Reply to Office Action of October 3, 2005

9. (withdrawn, currently amended) The method of claim 6, wherein the therapeutic oligonucleotide composition comprises an RNAi agent.

10. (withdrawn) The method of claim 9, wherein the RNAi agent is selected from the group consisting of oligonucleotides whose sequence consists essentially of a sequence as set forth in Seq. ID Nos. 16 to 23 or a sequence complementary thereto.